← Compound index
COMPOUND RECORD / PROSTATILEN

ProstatilenПростатилен

A prostate-tissue-derived polypeptide preparation with historical urological clinical reports. It is distinct from the synthetic short peptide Prostamax.

Source linked

What the studies found

Randomized study in people · 2022

Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation

Sperm DNA fragmentation after course 1
Median 10.23% (IQR 8.12–17.90) with Prostatilen AC.Lower than placebo by the reported rank test.p = 0.000022 between groups
Sperm DNA fragmentation after course 2
Median 6.91% (IQR 4.91–11.30) after two active courses.14.56% (IQR 13.96–16.50) after placebo then an active course.p = 0.00004 between groups
Seminal plasma antiradical activity
Reported between-group difference of +6.72% after course 1 and +23.7% after course 2.p = 0.02 and p = 0.0049, respectively

Sperm DNA fragmentation was lower after the first 10-day course with Prostatilen AC versus placebo (p = 0.000022). After a second course, medians were 6.91% in the two-active-course group and 14.56% in the placebo-then-active group.

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

More reported outcomes
Adverse events and PSA
12 reports of tenesmus or anal burning in 10 participants, with no treatment withdrawal or dosing change. The authors reported stable prostate-specific antigen.
Study notes · methods, sources and limitations

Participants or model 90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.

Design Double-blind, parallel, multicenter Phase IV study. Men received one 30 mg + 180 mg rectal suppository daily or matching placebo for 10 days. After a 21-day interval both arms received 10 days of active drug. DNA fragmentation was assessed using the TUNEL assay.

Important limitations

  • Both groups received active treatment in the second course. That comparison estimates the difference between two courses and one course. The trial evaluates a prostate extract and zinc-complex formulation, with no extract-only or zinc-only comparator. It measured semen markers and leaves pregnancy and live birth outcomes unanswered.

Experimental and Clinical Pharmacology. 2022;85(2):11–15. · Original journal report

Original source or citation ↗

Study results and tables ↗

Observational study · 2018

Prostatilen AC: three-month sperm DNA fragmentation follow-up

Mean sperm DNA fragmentation
17.8 ± 6.7% at baseline, 7.5 ± 4.2% at month 1, 10.2 ± 4.1% at month 2 and 16.2 ± 4.3% at month 3Table 1 reports p < 0.001, p < 0.05 and p ≥ 0.05, respectively, for each follow-up versus baseline.
Men with fragmentation above 30%
6/35 at baseline, 5/35 at month 1, 6/35 at month 2 and 6/35 at month 3.Table 2 reports no significant early change in this subgroup.

Mean sperm DNA fragmentation fell from 17.8% to 7.5% at month one, then rose to 10.2% at month two and 16.2% at month three. The month-three change from baseline was statistically inconclusive.

Study notes · methods, sources and limitations

Participants or model 35 men aged 21–46 with chronic nonbacterial prostatitis, reproductive disturbances and a partner with a history of missed miscarriage.

Design Two 10-day courses of daily rectal Prostatilen AC, 20 days apart, without other assigned medication. The paper describes the 30 mg prostate-extract formulation with 100 mg L-arginine and 23 mg zinc supplied by the zinc complex. Sperm chromatin structure was assessed by flow cytometry before and after treatment.

Important limitations

  • There was no concurrent comparison group. The authors used a laboratory outcome, and the study leaves pregnancy and live birth outcomes unanswered. The same group published a 25-person study in 2017 using a similar schedule and eligibility criteria. The extent of recruitment overlap is unclear.
  • The abstract and Table 1 give different p-value thresholds for the one-month result. The table values are used here.

Andrology and Genital Surgery. 2018;19(2):52–57. · Original journal report

Original source or citation ↗

Study results and tables ↗

Animal research · 2024

Kim’s five-peptide animal comparison: tables missing

Study of multiple preparations

Comparative preparations
Cortexin, Pineamin, Prostatilen, Thymalin and ThymogenChapter 6.4 title. Thymogen is a defined dipeptide; the five entries are not all tissue extracts.
Five-agent effect estimates
Original comparative tables not recoveredNo verified head-to-head result for Pineamin versus Cortexin, Thymalin, Thymogen or Prostatilen.

Named comparator in Chapter 6.4; original per-preparation outcomes are unavailable.

Study notes · methods, sources and limitations

Participants or model Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable

Design Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable

Important limitations

  • No established human environmental-performance result.
  • The 1990s Biorhythmology and Rang-97 records were reanalyzed; they are not new human recruits. The 2022–2024 physiology studies were separate. The conclusions do not provide numerical comparisons between the five preparations. The accessible account associates HIF-1α and TSPO measurements with stress physiology and discusses the nonpeptide DMAE derivative separately; a Pineamin-mediated biomarker mechanism is not established.
  • This is a documented animal comparison with inaccessible efficacy tables. Existing Pineamin reproductive studies establish a separate clinical setting, not evidence for physical performance or environmental resilience.

Kirov Military Medical Academy doctoral dissertation, 359 pp.; 2024 bibliography, related catalog entry dated 2025 · Dissertation

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Prostatilen

Names in this research collection

Prostate polypeptide complex

More study findings

Randomized study in people · 2023

Prostatilen AC and infrared laser therapy in 97 men with idiopathic infertility

Progressive sperm motility
29.2% to 37.1% with the combination28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alonep < 0.01 for the greater change with combination
Sperm DNA fragmentation
20.8% to 7.4% with the combination20.0% to 8.3% with laser and 21.2% to 9.8% with Prostatilen AC alonep < 0.05 for the greater change with combination
Adverse effects
The authors reported none during treatment or follow-up.

At two months, progressive sperm motility rose from 29.2% to 37.1% with the combination, versus 28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alone. The authors reported a greater change with the combination (p < 0.01).

Study notes · methods, sources and limitations

Participants or model 97 men with idiopathic infertility, randomized to laser (34), Prostatilen AC (31), or both treatments (32).

Design Ten infrared laser sessions on alternate days. Prostatilen AC arms received 30 mg prostate extract plus 180 mg zinc arginyl glycinate rectally at bedtime for 10 days, with a repeat course after five days. Follow-up was two months after treatment.

Important limitations

  • All three groups received active treatment at one center. The report leaves masking unclear. The follow-up focused on semen and hormone measures. The degree of participant overlap with earlier reports from the group is unclear.

Urology Herald. 2023;11(2):99–109. · Original journal report

Original source or citation ↗

Study results and tables ↗

Animal research · 2018

Original hypoxia, heat and cold results

Study of multiple preparations

Prostatilen · course hypoxia
7.0±5.6 min at 0.1 mg/kg versus 2.2±0.1 min salineAt 0.5 mg/kg: 4.2±0.7 min and a 66% increase in resistant animals as printed.0.1 mg/kg time p<0.01 as marked
Publication overlap
2014 Table 11 and 2018 Table 1 repeat the same valuesCounts as one reported experiment. Both publications also describe a distinct acute mouse screen.

The 2014 and 2018 course-hypoxia tables repeat the same experiment.

Study notes · methods, sources and limitations

Participants or model Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.

Design The single-dose mouse screen used 10,000 m, 8–10 per dose in the 2018 report (6–10 in the 2014 book). Table 1 instead reports a three-day rat series tested at 11,500 m the next day. Arm sizes for the repeated-dose table are not stated in the audited passage.

Important limitations

  • Separate mouse and rat protocols. Human performance was not assessed.
  • The 2018 rat course results and 2014 book table belong to one evidence family. The book omits an explicit course-series species and altitude in the adjacent paragraph. Short survival in an extreme animal model is separate from human endurance or safety.
  • The papers distinguish the single-dose mouse screen from the three-day rat protocol. The matching table adds no independent animals or human participants.

Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11 · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2014

Single intranasal exposure at simulated altitude

Study of multiple preparations

Prostatilen · number of complaints
0.2±0.2 vs 1.4±0.5Small short-term comparison.p<0.05 versus saline

Table 12 compares four small peptide arms with saline at 4,500 m.

Study notes · methods, sources and limitations

Participants or model Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.

Design Author-described random assignment. Exposure for 60–80 min at simulated 4,500 m with postural testing, a three-minute 100 W cycling load, motor tasks and blood measurements.

Important limitations

  • Participant overlap with the broader aerospace archive remains unresolved.
  • Small arms, numerous endpoints and several comparisons reported at p<0.1. Exact allocation counts and overlap with the Medilab lineage remain unresolved.
  • The 4,500 m protocol differs from Cheprasov’s 5,000 m comparison. Participant independence has not been established and this series adds no people to the historical tally.

Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12

Original source or citation ↗

Study results and tables ↗

Comparison in people · 1997

Cheprasov’s Medilab peptide comparisons in aerospace stress

Study of multiple preparations

Hypobaric comparison
Thymalin: 15–20% higher work measures; Cortexin: 10–15% improvement in selected operator measuresAbstract narrative; full arm-level estimates unavailable.
Coriolis motion tolerance
Cortexin +89%, Thymogen +73%, Epithalamin +68%Reported tolerance-time improvement relative to control, ten per arm.
Sustained work
Author reported recovery of selected Thymogen-group measures to baseline by three hoursFour per arm. Cortexin and oral Bemitil plus sydnocarb were separate comparators.

The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.

More reported outcomes
Postflight respiratory infections
1 of 4 in Thymogen arm versus 4 of 4 salineReported during the following year, a descriptive count from four pairs.
Program headcount
328 stated; stage rows add to 338The 116 and 8 are subseries, with no additional headcount contributed to the historical tally.
Study notes · methods, sources and limitations

Participants or model 116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.

Design Hypobaric test: three arms of 10 at 5,000 m for 60 min. Motion: seven arms of 10 in a Coriolis test. Work: four arms of four at 50% of individually tolerated load. Postflight: four mission pairs, one participant per pair given Thymogen.

Reported study exposure
Hypoxia: intranasal Cortexin or Thymalin, 20 mg per course over two days, or placebo. Motion: single intranasal 5 mg Thymalin, Cortexin, Prostatilen or Epithalamin, or 50 µg Thymogen, with oral scopolamine 0.1 mg and placebo controls. Work: nasal Thymogen 100 µg or Cortexin 10 mg before work and after 6 and 12 h, or oral sydnocarb plus Bemitil, or saline. Postflight: intranasal Thymogen 100 µg/day for seven days.

Important limitations

  • Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications.
  • Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications. The 47 modeling experts were outside the participant table.
  • The aerospace findings concern separate stress and recovery tasks, with no reliable pooled treatment effect.

Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Tissue-derived polypeptide complex
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Clinical reports linked; see study-specific limitations

Study methods

Original reports separated from narrative reviews and patents

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

New indexed primary abstracts and/or report reproductions linked; review depth shown per source

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PEPTIDE RESEARCH / OCT 2026

Related preparations and evidence

Evidence belongs to the preparation actually studied. A tissue extract and a synthetic peptide can belong to the same research tradition without having equivalent effects or safety.

Prostate: the molecular link

Prostatilen → Prostamax (adjacent short-peptide program)

Tissue-level research association only in this collection; direct molecular derivation of Prostamax from the clinical Prostatilen formulation has not been established.

Clinical evidence and limitations

Historical Prostatilen reports, a 127-patient Prostateks postoperative comparison and a separate 94-patient Prostateks prostatitis comparison are linked with distinct preparation identities.

The cited cohorts received Prostatilen. The uncontrolled results leave the treatment effect uncertain.

Related preparations

Some references concern related extracts, reviews or molecular identification rather than direct studies of this compound.

Explore the full bioregulator collection ↗

View this preparation in the Khavinson evidence map ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

1996 · RU2058780C1 · Prostatilen: smooth-muscle use claimsUse · 15/28 (54%) with Prostatilen versus 9/52 (17.3%) with symptomatic care

Reported findings

Prostatilen-containing care had more reported favorable short-term prostate outcomes, with no verified randomization.

Favorable conservative-treatment outcome
15/28 (54%) with Prostatilen versus 9/52 (17.3%) with symptomatic careAfter inpatient conservative carePatent-defined decision about unscheduled surgery
Residual urine ≤100 mL subgroup
11/11 favorable outcomes versus 7/19 in controlsSmall, potentially selected subgroups
All reported results, comparisons and limitations →

Use. The patent describes uses of Prostatilen involving prostate, bladder or venous smooth-muscle function.

The preparation is a tissue-derived complex; these claims do not establish equivalence to a defined synthetic prostate peptide.

Publication
RU2058780C1 ↗ · 1996-04-27
Earliest priority / filing
1992-11-17 / 1992-11-17
Original applicant / assignee
Совместное русско-американское акционерное общество закрытого типа "Неофарм"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
20132424 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Agent showing tonic action on the vein, bladder and prostate gland smooth muscle

Inventors: В.Х. Хавинсон; С.В. Серый; А.Л. Кожемякин; Р.И. Валеев.

RU2058780C1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Observational study · 2018

Prostatilen AC: three-month sperm DNA fragmentation follow-up

Mean sperm DNA fragmentation fell from 17.8% to 7.5% at month one, then rose to 10.2% at month two and 16.2% at month three. The month-three change from baseline was statistically inconclusive.

Mean sperm DNA fragmentation · 17.8 ± 6.7% at baseline, 7.5 ± 4.2% at month 1, 10.2 ± 4.1% at month 2 and 16.2 ± 4.3% at month 3 · Table 1 reports p < 0.001, p < 0.05 and p ≥ 0.05, respectively, for each follow-up versus baseline.

Study notes and original source
2018Uncontrolled human reportFull text available

Prostatilen AC: three-month sperm DNA fragmentation follow-up

Prostatilen AC rectal suppositories with prostate extract and zinc arginyl glycinate · Original journal report

S. Yu. Borovets, M. A. Rybalov, A. G. Gorbachev, S. Kh. Al-Shukri, A. V. Levina · Andrology and Genital Surgery. 2018;19(2):52–57.

Mean sperm DNA fragmentation fell from 17.8% to 7.5% at month one, then rose to 10.2% at month two and 16.2% at month three. The month-three change from baseline was statistically inconclusive.

Results and tables

Reported findings and study design

Two 10-day courses of daily rectal Prostatilen AC, 20 days apart, without other assigned medication. The paper describes the 30 mg prostate-extract formulation with 100 mg L-arginine and 23 mg zinc supplied by the zinc complex. Sperm chromatin structure was assessed by flow cytometry before and after treatment.

Population or model 35 men aged 21–46 with chronic nonbacterial prostatitis, reproductive disturbances and a partner with a history of missed miscarriage.

Results · Original article and Tables 1–2
MeasureResultComparison, timing and statistics
Mean sperm DNA fragmentation17.8 ± 6.7% at baseline, 7.5 ± 4.2% at month 1, 10.2 ± 4.1% at month 2 and 16.2 ± 4.3% at month 3Table 1 reports p < 0.001, p < 0.05 and p ≥ 0.05, respectively, for each follow-up versus baseline.
Men with fragmentation above 30%6/35 at baseline, 5/35 at month 1, 6/35 at month 2 and 6/35 at month 3.Table 2 reports no significant early change in this subgroup.

The abstract and Table 1 give different p-value thresholds for the one-month result. The table values are used here.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
35 men aged 21–46 with chronic nonbacterial prostatitis, reproductive disturbances and a partner with a history of missed miscarriage.
Source reviewed
Original Russian full article, methods and Tables 1–2.
Study limitations
  • There was no concurrent comparison group. The authors used a laboratory outcome, and the study leaves pregnancy and live birth outcomes unanswered.
  • The same group published a 25-person study in 2017 using a similar schedule and eligibility criteria. The extent of recruitment overlap is unclear.

Reviewed 2026-11-16.

Read the source ↗

Randomized study in people · 2022

Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation

Sperm DNA fragmentation was lower after the first 10-day course with Prostatilen AC versus placebo (p = 0.000022). After a second course, medians were 6.91% in the two-active-course group and 14.56% in the placebo-then-active group.

Sperm DNA fragmentation after course 1 · Median 10.23% (IQR 8.12–17.90) with Prostatilen AC. · Lower than placebo by the reported rank test. · p = 0.000022 between groups

Study notes and original source
2022Randomized trialFull text available

Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Prostatilen AC, 30 mg prostate extract plus 180 mg zinc arginyl glycinate per suppository · Original journal report

I. B. Yakovlev, S. V. Teplykh, M. A. Rybalov, S. Yu. Borovets, V. B. Vasilyuk, M. V. Faraponova, A. A. Krasnov, S. V. Petlenko, V. A. Apryatina · Experimental and Clinical Pharmacology. 2022;85(2):11–15.

Sperm DNA fragmentation was lower after the first 10-day course with Prostatilen AC versus placebo (p = 0.000022). After a second course, medians were 6.91% in the two-active-course group and 14.56% in the placebo-then-active group.

Results and tables

Reported findings and study design

Double-blind, parallel, multicenter Phase IV study. Men received one 30 mg + 180 mg rectal suppository daily or matching placebo for 10 days. After a 21-day interval both arms received 10 days of active drug. DNA fragmentation was assessed using the TUNEL assay.

Population or model 90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.

Results · Original journal PDF, trial flow, methods and results
MeasureResultComparison, timing and statistics
Sperm DNA fragmentation after course 1Median 10.23% (IQR 8.12–17.90) with Prostatilen AC.Lower than placebo by the reported rank test. · p = 0.000022 between groups
Sperm DNA fragmentation after course 2Median 6.91% (IQR 4.91–11.30) after two active courses.14.56% (IQR 13.96–16.50) after placebo then an active course. · p = 0.00004 between groups
Seminal plasma antiradical activityReported between-group difference of +6.72% after course 1 and +23.7% after course 2.p = 0.02 and p = 0.0049, respectively
Adverse events and PSA12 reports of tenesmus or anal burning in 10 participants, with no treatment withdrawal or dosing change. The authors reported stable prostate-specific antigen.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.
Source reviewed
Original journal PDF, recruitment, treatment sequence, adverse events and Figures 1–3.
Study limitations
  • Both groups received active treatment in the second course. That comparison estimates the difference between two courses and one course.
  • The trial evaluates a prostate extract and zinc-complex formulation, with no extract-only or zinc-only comparator. It measured semen markers and leaves pregnancy and live birth outcomes unanswered.

Reviewed 2026-11-16.

Read the source ↗

Randomized study in people · 2023

Prostatilen AC and infrared laser therapy in 97 men with idiopathic infertility

At two months, progressive sperm motility rose from 29.2% to 37.1% with the combination, versus 28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alone. The authors reported a greater change with the combination (p < 0.01).

Study notes and original source
2023Randomized trialFull text available

Prostatilen AC and infrared laser therapy in 97 men with idiopathic infertility

Prostatilen AC rectal suppositories, alone or with low-intensity infrared laser · Original journal report

M. K. Potapova, S. Yu. Borovets, S. Kh. Al-Shukri · Urology Herald. 2023;11(2):99–109.

At two months, progressive sperm motility rose from 29.2% to 37.1% with the combination, versus 28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alone. The authors reported a greater change with the combination (p < 0.01).

Results and tables

Reported findings and study design

Ten infrared laser sessions on alternate days. Prostatilen AC arms received 30 mg prostate extract plus 180 mg zinc arginyl glycinate rectally at bedtime for 10 days, with a repeat course after five days. Follow-up was two months after treatment.

Population or model 97 men with idiopathic infertility, randomized to laser (34), Prostatilen AC (31), or both treatments (32).

Results · Original full paper, treatment arms and Figures 2–4
MeasureResultComparison, timing and statistics
Progressive sperm motility29.2% to 37.1% with the combination28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alone · p < 0.01 for the greater change with combination
Sperm DNA fragmentation20.8% to 7.4% with the combination20.0% to 8.3% with laser and 21.2% to 9.8% with Prostatilen AC alone · p < 0.05 for the greater change with combination
Adverse effectsThe authors reported none during treatment or follow-up.
Mean semen measures at baseline and two months
Mean semen measures at baseline and two months
MeasureLaser (34)Prostatilen AC (31)Laser and Prostatilen AC (32)
Concentration (million/mL)50.9 → 53.247.1 → 52.149.8 → 56.4
Progressive motility (%)28.6 → 33.331.8 → 36.429.2 → 37.1
Morphologically normal forms (%)2.9 → 3.53.1 → 3.92.8 → 3.6
Sperm DNA fragmentation (%)20.0 → 8.321.2 → 9.820.8 → 7.4

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
97 men with idiopathic infertility, randomized to laser (34), Prostatilen AC (31), or both treatments (32).
Source reviewed
Original full article, methods, results and Figures 2–4. The matching conference abstract describes the same trial.
Study limitations
  • All three groups received active treatment at one center. The report leaves masking unclear.
  • The follow-up focused on semen and hormone measures. The degree of participant overlap with earlier reports from the group is unclear.

Reviewed 2026-11-16.

Read the source ↗

Animal research · 2018

Thymogen and four peptide preparations in hypoxia, heat and cold

The 2014 and 2018 course-hypoxia tables repeat the same experiment.

Study notes and original source
2018Animal / experimentalRussian-language source

Thymogen and four peptide preparations in hypoxia, heat and cold

· Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11

Format: Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177. · Reviewed: Reported methods, results and evidence limitations

E. B. Shustov, M. T. Gasanov, G. D. Kapanadze, Yu. V. Fokin, V. S. Novikov, E. L. Matveenko, Kh. Kh. Semenov · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11

In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.

Results and tables

Reported findings and study design

In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.

The single-dose mouse screen used 10,000 m, 8–10 per dose in the 2018 report (6–10 in the 2014 book). Table 1 instead reports a three-day rat series tested at 11,500 m the next day. Arm sizes for the repeated-dose table are not stated in the audited passage.

Population or model Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.

Dose, route and schedule

Historical animal protocol. Intraperitoneal dosing daily for three days for the course hypoxia series. Thymogen 0.001, 0.01 or 0.1 mg/kg, with distinct dose ranges for the other preparations.

Protocol source ↗ · Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177.

Results · Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177.
MeasureResultComparison, timing and statistics
Thymogen · course hypoxia10.6±3.2, 20.1±11.1 and 28.6±11.8 minAt 0.001, 0.01 and 0.1 mg/kg respectively. Saline 2.2±0.1 min. · p<0.05, p<0.01 and p<0.01 versus saline as marked.
Thymalin · course hypoxia7.1±2.6 min at 0.1 mg/kg versus 2.2±0.1 min saline0.5 mg/kg arm was unmarked for significance. · p<0.05 for 0.1 mg/kg
Cortexin · course hypoxia and heat5.2±3.2 min at 1 mg/kg in hypoxia; 88.6±2.4 vs 96.5±5.2 min at 5 mg/kg in heatSeparate stress experiments and different doses. The heat endpoint shortened. · Both selected contrasts p<0.05 as marked
Prostatilen · course hypoxia7.0±5.6 min at 0.1 mg/kg versus 2.2±0.1 min salineAt 0.5 mg/kg: 4.2±0.7 min and a 66% increase in resistant animals as printed. · 0.1 mg/kg time p<0.01 as marked
Epithalamin · course hypoxia and cold7.4±4.5 min at 10 mg/kg in hypoxia; 194±22 vs 168±12 min at 0.5 mg/kg in air coolingSeparate dose and stress protocols. 1 mg/kg hypoxia arm was unmarked. · Both selected contrasts p<0.05 as marked
Thymogen · air cooling185±25 vs 168±12 min to rectal temperature of 35°C0.05 mg/kg versus control. No significant contrast marked.
Publication overlap2014 Table 11 and 2018 Table 1 repeat the same valuesCounts as one reported experiment. Both publications also describe a distinct acute mouse screen.
Matched course-hypoxia data · 2014 Table 11 and 2018 Table 1
Matched course-hypoxia data · 2014 Table 11 and 2018 Table 1
ArmDose (mg/kg unless noted)Time (min)Reported change (%)Resistant-animal share increase (%)
Saline1.0 as printed2.2±0.100
Thymalin0.17.1±2.6*23838
Thymalin0.53.7±1.07616
Thymalin1.04.4±2.2*11016
Cortexin0.13.9±1.4865
Cortexin0.53.8±0.4*8116
Cortexin1.05.2±3.2*1485
Prostatilen0.17.0±5.6**2330
Prostatilen0.54.2±0.7*10066*
Prostatilen1.02.4±1.01416
Epithalamin0.12.7±0.62215
Epithalamin1.01.8±0.500
Epithalamin10.07.4±4.5*23633
Thymogen0.00110.6±3.2*40548*
Thymogen0.0120.1±11.1**85760*
Thymogen0.128.6±11.8**126280**

M±m. * p<0.05, ** p<0.01 versus saline. Percentage column transcribed as printed and may differ from calculations using rounded means. The book’s adjacent mouse protocol describes the acute screen.

The papers distinguish the single-dose mouse screen from the three-day rat protocol. The matching table adds no independent animals or human participants.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
Source reviewed
Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177.
Study limitations
  • The 2018 rat course results and 2014 book table belong to one evidence family. The book omits an explicit course-series species and altitude in the adjacent paragraph.
  • Short survival in an extreme animal model is separate from human endurance or safety.

Reviewed 2026-11-09.

Read the source ↗

Comparison in people · 2014

Four intranasal peptide arms at simulated 4,500 m

Table 12 compares four small peptide arms with saline at 4,500 m.

Study notes and original source
2014Human comparative studyRussian-language source

Four intranasal peptide arms at simulated 4,500 m

· Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12

Format: Original publication and selected methods and results checked · Reviewed: Reported methods, results and evidence limitations

N. N. Karkishchenko, V. V. Uyba, V. N. Karkishchenko, E. B. Shustov, K. V. Kotenko, S. L. Lyublinskiy · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12

Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.

Results and tables

Reported findings and study design

Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.

Author-described random assignment. Exposure for 60–80 min at simulated 4,500 m with postural testing, a three-minute 100 W cycling load, motor tasks and blood measurements.

Population or model Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.

Dose, route and schedule

Single intranasal administration one hour before ascent: Thymogen 1 µg, Cortexin 10 mg, Epithalamin 10 mg or Prostatilen 5 mg. The control received equivalent-volume saline.

Protocol source ↗ · Original publication and selected methods and results checked

Results · Original publication and selected methods and results checked
MeasureResultComparison, timing and statistics
Thymogen · blood lactate1.81±0.21 vs 2.98±0.46Source Table 12 units not specified on the row. · p<0.05 versus saline
Cortexin · complex visuomotor reaction latency423±12 vs 381±9 msSlower response, even with some favorable markers. · p<0.01 versus saline
Epithalamin · number of complaints0.33±0.13 vs 1.4±0.5Authors marked a trend. · p<0.1 versus saline
Prostatilen · number of complaints0.2±0.2 vs 1.4±0.5Small short-term comparison. · p<0.05 versus saline

The 4,500 m protocol differs from Cheprasov’s 5,000 m comparison. Participant independence has not been established and this series adds no people to the historical tally.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
Source reviewed
Original publication and selected methods and results checked
Study limitations
  • Small arms, numerous endpoints and several comparisons reported at p<0.1. Exact allocation counts and overlap with the Medilab lineage remain unresolved.

Reviewed 2026-11-09.

Read the source ↗

Comparison in people · 1997

Cheprasov’s Medilab peptide comparisons in aerospace stress

The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.

Study notes and original source
1997Human comparative studyRussian-language source

Cheprasov’s Medilab peptide comparisons in aerospace stress

· Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods

Format: Author’s abstract transcription. Full dissertation and underlying records unavailable. · Reviewed: Reported methods, results and evidence limitations

V. V. Cheprasov · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods

The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.

Results and tables

Reported findings and study design

The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.

Hypobaric test: three arms of 10 at 5,000 m for 60 min. Motion: seven arms of 10 in a Coriolis test. Work: four arms of four at 50% of individually tolerated load. Postflight: four mission pairs, one participant per pair given Thymogen.

Population or model 116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.

Dose, route and schedule

Hypoxia: intranasal Cortexin or Thymalin, 20 mg per course over two days, or placebo. Motion: single intranasal 5 mg Thymalin, Cortexin, Prostatilen or Epithalamin, or 50 µg Thymogen, with oral scopolamine 0.1 mg and placebo controls. Work: nasal Thymogen 100 µg or Cortexin 10 mg before work and after 6 and 12 h, or oral sydnocarb plus Bemitil, or saline. Postflight: intranasal Thymogen 100 µg/day for seven days.

Protocol source ↗ · Author’s abstract transcription. Full dissertation and underlying records unavailable.

Results · Author’s abstract transcription. Full dissertation and underlying records unavailable.
MeasureResultComparison, timing and statistics
Hypobaric comparisonThymalin: 15–20% higher work measures; Cortexin: 10–15% improvement in selected operator measuresAbstract narrative; full arm-level estimates unavailable.
Coriolis motion toleranceCortexin +89%, Thymogen +73%, Epithalamin +68%Reported tolerance-time improvement relative to control, ten per arm.
Sustained workAuthor reported recovery of selected Thymogen-group measures to baseline by three hoursFour per arm. Cortexin and oral Bemitil plus sydnocarb were separate comparators.
Postflight respiratory infections1 of 4 in Thymogen arm versus 4 of 4 salineReported during the following year, a descriptive count from four pairs.
Program headcount328 stated; stage rows add to 338The 116 and 8 are subseries, with no additional headcount contributed to the historical tally.

The aerospace findings concern separate stress and recovery tasks, with no reliable pooled treatment effect.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
Source reviewed
Author’s abstract transcription. Full dissertation and underlying records unavailable.
Study limitations
  • Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications.
  • The 47 modeling experts were outside the participant table.

Reviewed 2026-11-09.

Read the source ↗

Animal research · 2024

Kim’s five-peptide comparison in animal stress experiments

Named comparator in Chapter 6.4; original per-preparation outcomes are unavailable.

Study notes and original source
2024Animal / experimentalRussian-language source

Kim’s five-peptide comparison in animal stress experiments

· Dissertation

Format: Dissertation catalog, Chapter 6.4 heading, methods summary and conclusions; 49-page author abstract cataloged but not retrieved; original comparison tables unavailable · Reviewed: Reported methods, results and evidence limitations

A. E. Kim · Kirov Military Medical Academy doctoral dissertation, 359 pp.; 2024 bibliography, related catalog entry dated 2025

The chapter identifies Cortexin, Pineamin, Prostatilen, Thymalin and Thymogen. The author highlights Pineamin in conclusions; original outcome tables and dose schedules have not been recovered.

Results and tables

Reported findings and study design

The chapter identifies Cortexin, Pineamin, Prostatilen, Thymalin and Thymogen. The author highlights Pineamin in conclusions; original outcome tables and dose schedules have not been recovered.

Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable

Population or model Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable

Protocol information

Peptide doses, routes, group assignments and timing require Chapter 6.4. The separate 25 mg/kg DMAE derivative was not Pineamin or another peptide.

Protocol source ↗ · Dissertation catalog, Chapter 6.4 heading, methods summary and conclusions; 49-page author abstract cataloged but not retrieved; original comparison tables unavailable

Results · Dissertation catalog, Chapter 6.4 heading, methods summary and conclusions; 49-page author abstract cataloged but not retrieved; original comparison tables unavailable
MeasureResultComparison, timing and statistics
Comparative preparationsCortexin, Pineamin, Prostatilen, Thymalin and ThymogenChapter 6.4 title. Thymogen is a defined dipeptide; the five entries are not all tissue extracts.
Pineamin · animal stress modelsAuthor highlights resistance to hypoxia, heat and coldSelected conclusions only; dose, sample sizes, numerical results and ranking unavailable.
Five-agent effect estimatesOriginal comparative tables not recoveredNo verified head-to-head result for Pineamin versus Cortexin, Thymalin, Thymogen or Prostatilen.
HIF-1α and TSPOPredictive-marker hypothesis; peptide-specific causal data unavailableThe DMAE derivatives were evaluated in separate nonpeptide groups.
Document acquisition49-page dissertation abstract with tables cataloged in 2024Find the original author abstract and Chapter 6.4 before updating any ranking.

This is a documented animal comparison with inaccessible efficacy tables. Existing Pineamin reproductive studies establish a separate clinical setting, not evidence for physical performance or environmental resilience.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable
Source reviewed
Dissertation catalog, Chapter 6.4 heading, methods summary and conclusions; 49-page author abstract cataloged but not retrieved; original comparison tables unavailable
Study limitations
  • The 1990s Biorhythmology and Rang-97 records were reanalyzed; they are not new human recruits. The 2022–2024 physiology studies were separate.
  • The conclusions do not provide numerical comparisons between the five preparations.
  • The accessible account associates HIF-1α and TSPO measurements with stress physiology and discusses the nonpeptide DMAE derivative separately; a Pineamin-mediated biomarker mechanism is not established.

Reviewed 2026-11-08.

Read the source ↗

Experiment described in a patent · 1996

Prostatilen: smooth-muscle use claims — RU2058780C1

Prostatilen-containing care had more reported favorable short-term prostate outcomes, with no verified randomization.

Favorable conservative-treatment outcome · 15/28 (54%) with Prostatilen versus 9/52 (17.3%) with symptomatic care · Patent-defined decision about unscheduled surgery · After inpatient conservative care

Study notes and original source
1996Patent / reported experimentsFull text available

Prostatilen: smooth-muscle use claims — RU2058780C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

В.Х. Хавинсон, С.В. Серый, А.Л. Кожемякин, Р.И. Валеев · RU2058780C1 · patent family 20132424

Prostatilen-containing care had more reported favorable short-term prostate outcomes, with no verified randomization.

Results and tables

Reported patent results

Reported findings

Prostatilen-containing care had more reported favorable short-term prostate outcomes, with no verified randomization.

Patent reports include a 23-patient incontinence series and a separate prostate-adenoma comparison: 28 adjunctively treated versus 52 symptomatic-care patients.

Population or model Patent reports include a 23-patient incontinence series and a separate prostate-adenoma comparison: 28 adjunctively treated versus 52 symptomatic-care patients.

Results · Description: clinical incontinence observations and stage-II adenoma comparison.
MeasureResultComparison, timing and statistics
Favorable conservative-treatment outcome15/28 (54%) with Prostatilen versus 9/52 (17.3%) with symptomatic carePatent-defined decision about unscheduled surgery · After inpatient conservative care
Residual urine ≤100 mL subgroup11/11 favorable outcomes versus 7/19 in controlsSmall, potentially selected subgroups
Incontinence seriesNear-complete cessation of involuntary urination in 17/23; sphincter-tone normalization in 15/23Separate uncontrolled series, not part of the 28-versus-52 comparison

Concurrent treatment, nonrandom allocation and short-term clinical decisions prevent a reliable comparative efficacy estimate. Each cohort has its own response rate.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Patent reports include a 23-patient incontinence series and a separate prostate-adenoma comparison: 28 adjunctively treated versus 52 symptomatic-care patients.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The preparation is a tissue-derived complex; these claims do not establish equivalence to a defined synthetic prostate peptide.
  • Concurrent treatment, nonrandom allocation and short-term clinical decisions prevent a reliable comparative efficacy estimate. Each cohort has its own response rate.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Lab research · 2015

[POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS].

Prostatilen was among the calf-tissue preparations tested in corresponding rat organotypic cultures. The abstract reports tissue-growth and marker changes across the preparations; it does not provide a separate numerical effect estimate for this preparation.

Study notes and original source
2015In vitroEnglish abstract

[POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS].

· Original journal report

Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN · Advances in gerontology = Uspekhi gerontologii · PMID 26390619

Calf-tissue preparations, including Ventvil, stimulated corresponding tissue-culture growth with changes in proliferation-related markers.

Population / setting
Organotypic tissue cultures from young and old rats
Source reviewed
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
  • Tissue-culture growth is not organ regeneration in patients; equivalence to current branded products is unverified.
  • Full methods, reporting completeness and independent replication remain to be appraised.

Reviewed 2026-10-05.

Read the source ↗

Review of earlier studies · 2013

Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results

Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.

Study notes and original source
2013ReviewEnglish abstract

Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results

Khavinson VKh, Kuznik BI, Ryzhak GA · Adv Gerontol 26(1):20-37. PMID 24003726

Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.

Population / setting
Originating group’s clinical and gerontology literature
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • Review by investigators in the originating program; not independent replication.
  • Clinical findings must be traced to the exact preparation and original study.

Reviewed 2026-09-29.

Read the source ↗

Observational study · 1991

The use of prostatilen in treating patients with chronic prostatitis

An uncontrolled 307-person chronic-prostatitis series reported symptom disappearance or attenuation in 96.7% after Prostatilen.

Study notes and original source
1991Uncontrolled human reportEnglish abstract

The use of prostatilen in treating patients with chronic prostatitis

Tkachuk VN, Gorbachev AG, Khavinson VKh · Urol Nefrol (Mosk) (6):40-43. PMID 1823682

An uncontrolled 307-person chronic-prostatitis series reported symptom disappearance or attenuation in 96.7% after Prostatilen.

Results and tables

Reported findings and study design

An uncontrolled 307-person chronic-prostatitis series reported symptom disappearance or attenuation in 96.7% after Prostatilen.

307 patients aged 18–74; disease duration 4 months–36 years; assessments at treatment completion and 4–6 months later.

Dose, route and schedule

Prostatilen: 5–10 mg intramuscularly once daily for five to ten days.

Protocol source ↗ · Indexed publication abstract

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Reported symptom response96.7%Disappearance or attenuation; uncontrolled composite clinical response
Onset of responseAfter 2–3 injections; greatest reported response after 5–6Descriptive clinical observation
Studied regimen5–10 mg intramuscularly daily for 5–10 days
Participants307

The abstract does not give a placebo response, a validated symptom-score change or separate response rates at each follow-up. Its claim of no side effects is not a systematic incidence estimate.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
307 men with chronic prostatitis
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • The abstract does not establish a randomized concurrent control.
  • Reported tolerability cannot establish long-term safety; findings do not apply to Prostamax.

Reviewed 2026-11-01.

Read the source ↗

Observational study · 1991

The use of prostatilen in treating patients with prostatic diseases

Describes changes in symptoms, urinary measures and reproductive-function measures with Prostatilen.

Study notes and original source
1991Uncontrolled human reportEnglish abstract

The use of prostatilen in treating patients with prostatic diseases

Vozianov AF, Gorpinchenko II, Boĭko NI, Drannik GN, Khavinson VKh · Urol Nefrol (Mosk) (6):43-46. PMID 1823683

Describes changes in symptoms, urinary measures and reproductive-function measures with Prostatilen.

Results and tables

Reported findings and study design

Prostatilen clinical report: 37 patients with chronic prostatitis and 15 with prostatic adenoma.

Population or model 37 patients with chronic prostatitis and 15 with prostatic adenoma

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Symptoms, uroflow and semen measuresChanges reportedNumerical outcome values and comparator data absent
Adverse reactionsNone reported in this small study

Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
37 patients with chronic prostatitis and 15 with prostatic adenoma
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • Small mixed clinical groups; control methods and adverse-event ascertainment unclear from the abstract.
  • The tissue extract is not the synthetic peptide Prostamax.

Reviewed 2026-09-29.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗